Article
Rheumatology
Daniel H. Solomon, Jon T. Giles, Katherine P. Liao, Paul M. Ridker, Pamela M. Rist, Robert J. Glynn, Rachel Broderick, Fengxin Lu, Meredith T. Murray, Kathleen Vanni, Leah M. Santacroce, Shady Abohashem, Philip M. Robson, Zahi Fayad, Venkatesh Mani, Ahmed Tawakol, Joan Bathon
Summary: This study found that adding either a TNFi or triple therapy led to clinically important improvements in vascular inflammation. However, adding a TNFi did not reduce arterial inflammation more than triple therapy.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Jeffrey R. Curtis, Kunihiro Yamaoka, Yi-Hsing Chen, Deepak L. Bhatt, Levent M. Gunay, Naonobu Sugiyama, Carol A. Connell, Cunshan Wang, Joseph Wu, Sujatha Menon, Ivana Vranic, Juan J. Gomez-Reino
Summary: This study evaluated malignancies and their associations with baseline risk factors and cardiovascular risk scores in patients with rheumatoid arthritis (RA) treated with tofacitinib and tumour necrosis factor inhibitors (TNFi). The results showed that the risk of malignancies was increased with tofacitinib compared to TNFi, and the highest incidence was observed in patients with a history of atherosclerotic cardiovascular disease (HxASCVD) or increasing cardiovascular risk.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Roy Fleischmann, Jeffrey R. Curtis, Christina Charles-Schoeman, Eduardo Mysler, Kunihiro Yamaoka, Christophe Richez, Hannah Palac, Deanne Dilley, Jianzhong Liu, Sander Strengholt, Gerd Burmester
Summary: A post hoc analysis was conducted to assess the potential risk of upadacitinib in a high-risk population of patients with rheumatoid arthritis (RA). The results showed that while there was an increased risk of major adverse cardiovascular events (MACE), malignancy (excluding non-melanoma skin cancer), and venous thromboembolism (VTE) in the high-risk populations, the risk was comparable between upadacitinib-treated and adalimumab-treated patients.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Immunology
Ming-Han Chen, Shan-Fu Yu, Jia-Feng Chen, Wei-Sheng Chen, The-Ling Liou, Chung-Tei Chou, Chung-Yuan Hsu, Han-Ming Lai, Ying-Chou Chen, Chang-Youh Tsai, Tien-Tsai Cheng
Summary: The study compared the impact of different treatment regimens for rheumatoid arthritis on patients' bone mineral density, finding that abatacept may have a better effect in preserving bone density. Anti-osteoporosis therapy can prevent systemic bone loss in patients regardless of the type of rheumatoid arthritis treatment.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Siri Lillegraven, Nina Paulshus Sundlisaeter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Ase Stavland Lexberg, Tor Magne Madland, Hallvard Fremstad, Christian A. Hoili, Gunnstein Bakland, Cristina Spada, Hilde Haukeland, Inger Myrnes Hansen, Ellen Moholt, Till Uhlig, Daniel H. Solomon, Desiree Van der Heijde, Tore K. Kvien, Espen A. Haavardsholm
Summary: This study aimed to assess the effect of tapering tumor necrosis factor inhibitor (TNFi) to withdrawal compared with stable treatment on the risk of disease activity flares in patients with rheumatoid arthritis (RA) in remission for more than 1 year. The results showed that in the tapering TNFi group, 63% experienced a flare during 12 months, compared to 5% in the stable TNFi group. Therefore, tapering TNFi to discontinuation is not non-inferior to continued stable treatment.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Samantha Louise Smith, Sheree Alexander, Nisha Nair, Sebastien Viatte, Stephen Eyre, Kimme L. Hyrich, Ann W. Morgan, Anthony G. Wilson, John D. Isaacs, Darren Plant, Anne Barton
Summary: The study aimed to explore whether the inflammatory protein MRP8/14 can serve as a biomarker for treatment response in rheumatoid arthritis (RA) patients receiving tumor necrosis factor (TNF) inhibitors. The results showed that in the 3-component and 2-component models, patients with high pre-treatment levels of MRP8/14 were 1.92 and 2.03 times more likely to be classified as EULAR responders compared to those with low levels. However, no significant associations were observed in the 4-component model. Conclusion: Apart from its correlation with CRP, there is no evidence to suggest that MRP8/14 explains additional variability in response to TNFi in RA patients beyond CRP alone.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Roy Fleischmann, Eduardo Mysler, Louis Bessette, Charles G. Peterfy, Patrick Durez, Yoshiya Tanaka, Jerzy Swierkot, Nasser Khan, Xianwei Bu, Yihan Li, In-Ho Song
Summary: This study assessed the long-term safety and efficacy of the Janus kinase inhibitor upadacitinib compared to adalimumab in patients with active rheumatoid arthritis. The results showed that upadacitinib had numerically better clinical responses than adalimumab over a period of 3 years, and the adverse event rates were generally comparable between the two drugs, although certain adverse events were reported at higher rates with upadacitinib.
Article
Rheumatology
Yu-Jih Su, Hui-Ming Chen, Tien-Ming Chan, Tien-Tsai Cheng, Shan-Fu Yu, Jia-Feng Chen, Chun-Yu Lin, Chung-Yuan Hsu
Summary: This study aimed to investigate whether patients using disease-modifying anti-rheumatic drugs (DMARDs) may have different levels of risk for diabetes and to analyze other risk factors for diabetes. The results showed that certain DMARDs can reduce the risk of diabetes.
Article
Rheumatology
Hieronymus T. W. Smeele, Esther Roder, Annemarie G. M. G. J. Mulders, Eric A. P. Steegers, Radboud J. E. M. Dolhain
Summary: This study is the first to show that the use of TNFi during pregnancy is associated with increased birth weight in offspring of women with well-controlled RA. Further research is needed to explore the underlying mechanism of TNF inhibition on birth weight and its long-term consequences for the offspring.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Benedicte Delcoigne, Tine Iskov Kopp, Elizabeth Arkema, Karin Hellgren, Sella Aarrestad Provan, Heikki Relas, Kalle Aaltonen, Nina Trokovic, Bjorn Gudbjornsson, Gerdur Grondal, Eirik Klami Kristianslund, Jesper Lindhardsen, Lene Dreyer, Johan Askling
Summary: This study compared the incidences of neuroinflammatory events in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) starting a tumor necrosis factor inhibitor (TNFi). The results showed that the choice of specific TNFi did not seem to play an important role in the risk of neuroinflammatory events.
Article
Rheumatology
Nafise Ghalandari, Maarten M. Immink, Esther Roeder, Patricia C. J. Bruijning-Verhagen, Hieronymus Smeele, Hubertina Crijns, Nicoline A. T. van der Maas, Mireille N. Bekker, Elisabeth A. M. Sanders, Radboud J. E. M. Dolhain
Summary: This pilot study investigated the impact of TNFis treatment in pregnant women with rheumatic disease on Tdap vaccine responses and maternal anti-pertussis IgG antibody levels in newborns. The results showed lower levels of maternal anti-pertussis antibodies in newborns during TNFis treatment.
Article
Medicine, General & Internal
Hyun Jin Park, Boyoon Choi, Yun-Kyoung Song, Yoon-Jeong Oh, Eun Bong Lee, In-Wha Kim, Jung Mi Oh
Summary: This study aimed to evaluate the association between the use of TNFi and the risk of NTM infection in patients with rheumatoid arthritis (RA). Using the Korean National Health Insurance Service database, the study found that TNFi use was not associated with an increased risk of NTM infection compared to csDMARDs.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Rheumatology
Paolo Gisondi, Francesco Bellinato, Giovanni Targher, Luca Idolazzi, Giampiero Girolomoni
Summary: In patients with moderate-to-severe chronic plaque psoriasis, treatment with bDMARDs may delay or reduce the risk of incident PsA. The annual incidence rate of PsA was significantly lower in the bDMARDs group compared to the phototherapy group. Factors associated with a higher risk of PsA included older age, nail psoriasis, and psoriasis duration over 10 years.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Johan Law-Wan, Marc-Antoine Sparfel, Sophie Derolez, Nicolas Azzopardi, Philippe Goupille, Jacqueline Detert, Denis Mulleman, Theodora Bejan-Angoulvant
Summary: In rheumatoid arthritis (RA), patients who are more responsive to TNFi are those who are non-obese, have a longer disease duration, and have a higher initial disease activity. Results from analyzing individual data of 11,617 patients from 29 RCTs highlight the importance of these patient characteristics in predicting responsiveness to TNFi therapy.
Article
Rheumatology
Erik Kemper, Nafise Ghalandari, Hetty Wintjes, Anneke Van Steensel-Boon, Laura Kranenburg, Annemarie Mulders, Hubertina Crijns, Hieronymus Smeele, Radboud J. E. M. Dolhain
Summary: The study shows that patients with RA are more likely to breast feed their offspring, which may be attributed to the availability of lactation-compatible medication and pregnancy counseling. The breastfeeding rates among patients with RA are similar to those in the general population.